Market Overview

Sigma® Life Science Licenses Efflux Transporter Knockout Human Cell-Based Assays


Sigma-Aldrich® Corporation (NASDAQ: SIAL) today announced that Sigma Life Science, its innovative biological products and services business, initiated a licensing program aimed at contract research organizations (CROs) and pharmaceutical companies for its novel CompoZr® Transporter Knockout Cell Lines for preclinical ADME screening and safety studies. Complete functional knockouts of transporters in the intestinal cell line (Caco-2) enables identification of critical safety and efficacy characteristics compared to current chemical inhibitor-based assays and more precise determination of a drug candidate's potential drug–drug interactions. Cyprotex, a leading ADME-Tox service company with sites in both the UK and USA, is the first non-exclusive licensee in the program. For more information, visit

The U.S. Food and Drug Administration and the European Medicines Agency recently recommended defining a drug candidate's interactions with efflux transporters, which act as doorways for drugs to exit or be expelled from human cells, to ascertain a drug candidate's probable safety profile and potential for adverse drug–drug interactions. Current efflux transporter assays use standard chemical inhibitors that can interact with multiple transporters

See full press release

Posted-In: News Guidance Contracts Global


Related Articles (SIAL)

View Comments and Join the Discussion!

Partner Center